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Meta-analysisa b s t r a c t
The immunogenicity benefit of inactivated influenza vaccine (IIV) adjuvanted by squalene over non-
adjuvanted aqueous IIV was explored in a meta-analysis involving 49 randomised trials published
between 1999 and 2017, and 22,470 eligible persons of all age classes. Most vaccines contained 15 lg
viral haemagglutinin per strain. Adjuvanted IIV mostly contained 9.75 mg squalene per dose.
Homologous pre- and post-vaccination geometric mean titres (GMTs) of haemagglutination-inhibition
(HI) antibody were recorded for 290 single influenza (sub-)type arms. The adjuvant effect was expressed
as the ratio of post-vaccination GMTs between squalene-IIV and aqueous IIV (GMTR, 145 estimates).
GMTRs > 1.0 favoured squalene-IIV over aqueous IIV. For all influenza (sub-)types, the adjuvant effect
proved negatively associated with pre-vaccination GMT and mean age. The adjuvant effect appeared
most pronounced in young children (mean age < 2.5 years) showing an average GMTR of 3.7 (95% CI:
2.5 to 5.5). With increasing age, GMTR values gradually decreased towards 1.4 (95% CI: 1.0 to 1.9) in older
adults. Heterologous antibody titrations simulating mismatch between vaccine and circulating virus (30
GMTR estimates) again showed a larger adjuvant effect at young age. GMT values and their variances
were converted to antibody-predicted protection rates using an evidence-based clinical protection curve.
The adjuvant effect was expressed as the protection rate differences, which showed similar age patterns
as corresponding GMTR values. However for influenza B, the adjuvant effect lasted longer than for influ-
enza A, possibly due to a generally later influenza B virus exposure. Collectively, this meta-analysis indi-
cates the highest benefit of squalene-IIV over aqueous IIV in young children and decreasing benefit with
progressing age. This trend is similar for seasonal influenza (sub-)types and the 2009 pandemic strain, by
both homologous and heterologous titration. The impact of pre-seasonal immunity on vaccine effective-
ness, and its implications for age-specific vaccination recommendations, are discussed.
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Inactivated influenza vaccine (IIV) can be formulated as aque-
ous suspension or as emulsion. MF59 is an oil-in-water emulsion
developed in the 1990ies [1]. Its oily constituent is squalene [2], a
non-toxic and metabolisable lipid, naturally produced in liver cells
as intermediate in cholesterol synthesis. Squalene in water, when
processed under high pressure and stabilised by surfactants
(polysorbate 80 and sorbitan trioleate), forms small oil droplets
(~160 nm). The emulsion modulates cell- and cytokine-driven
immune pathways at the injection site and local lymph nodes
eventually leading to the induction of T-cell dependent, specific
anti-HA antibodies against the vaccine antigens [3].
A meta-analysis that we published previously [4], described the
immunogenicity and safety of IIV for intramuscular or subcuta-
neous application, as assessed in 33 eligible randomised controlled
trials (RCTs) published between 1978 and 2009. Main immuno-
genic variables were the homologous post-vaccination geometric
mean titre (post-GMT) for a vaccine arm, and the post-GMT ratio
(GMTR) for a comparison of two vaccine arms within a randomised
trial. It was found that the respective formulations of aqueous (not
adjuvanted) IIV (whole virus, split, subunit and virosomal) were
similar in mutual comparisons, and squalene-adjuvanted IIV
induced, on average, modestly larger antibody titres than aqueous
IIV (pooled GMTR  1.4-fold). The latter was based on a subset of
13 RCTs, all but one performed in middle-aged and older adults.
The only RCT, which had been conducted in young children, pro-
vided larger GMTR values. Whether the latter observation was
indicative of a generally larger adjuvant effect in children com-
pared to adults, i.e., of an association between adjuvant effect
and pre-vaccination immunity, could not be decided on the basis
of one RCT only.
In the meantime, more RCTs comparing squalene-IIV with
aqueous IIV have been performed and published, in particular
stimulated by the influenza A pandemic in 2009. The new clinical
evidence warrants an update of the former investigation, and the
larger number of trials in the respective age classes allows to
explore the association between measures of pre-vaccination
immunity (i.e., mean age and pre-vaccination GMT) and the adju-
vant effect of squalene.
Squalene adjuvancy was expressed as homologous GMTR, and,
at least in a few trials, also as heterologous GMTR. Heterologous
titrations (with a virus strain deviant from the vaccine strain)
may predict how a vaccine would perform in the field in case of
mismatch between vaccine strain and circulating strain. Moreover,
since the work of Coudeville et al. [9] on the association between
antibody titre and the chance of clinical protection against infec-
tion, antibody data can be transformed to antibody-predicted clin-
ical protection rate (PRab) estimates, which may provide a more
relevant indication for real vaccine performance in the field than
antibody levels.
Safety data (local and systemic vaccine reactions and serious
adverse events) in the 2011meta-analysis revealed a slightly largerchance of local vaccine reactions for squalene-IIV, compared with
aqueous IIV, in accordance with Pellegrini et al. 2009 [5] and Mon-
tana et al. 2010 [6], This is a finding of only marginal clinical impor-
tance in the light of the favourable safety profile of current
inactivated influenza vaccines in general. This study does not con-
sider safety data.
2. Materials and methods
2.1. Literature search and sources
Aim of the literature search was to identify all published articles
describing randomised comparative immunogenicity trials
between squalene-adjuvanted subunit IIV and aqueous IIV, and
meeting the inclusion requirements as given in Table 1.
The literature search for the meta-analysis by Beyer et al. 2011
[4] was repeated and extended until December 12, 2018, with an
improved keyword algorithm: The previously used keyword
‘MF590 was replaced by ‘MF59*’ as it had turned out that the pre-
vious search could not always capture composed terms like MF59TM
or MF59 in title or abstract. Reviews and meta-analyses identified
in the search were exerted as additional sources for candidate arti-
cles (umbrella literature search strategy).
2.2. Treatment of trial variables, and data arrangement
Trial variables related to pre-vaccination immunity: In a pro-
visional analysis, mean age, pre-vaccination GMT (pre-GMT), his-
tory of previous vaccinations and health state showed a strongly
1616 W.E.P. Beyer et al. / Vaccine 38 (2020) 1614–1622positive correlation - in general, the higher the mean age of a trial
population, the larger also the pre-GMT, the rate of previous vacci-
nations and the fraction of chronically ill persons. From single lin-
ear regression models with ln GMTR as dependent variable and for
any of the trial variables, the coefficient of determination (R2) was
estimated as a measure of predictability. R2-values were largest
(up to 73%) and most significant for mean age, which was therefore
chosen to represent pre-vaccination immunity. Pre-GMT values
arranged according to year of trial, strongly varied, which may
reflect previous virus circulation within the respective trial popula-
tions. For seasonal strains, no long-term time trend was detected.
For the pandemic A-H1N1 strain, pre-GMT values increased in
the period 2009 to 2015 in all mean age classes.
Age-defined classification of trials. Trials varied in their age
ranges and could be narrow (e.g., 1.5 to 3 years) or broad (e.g., 65
to 88 years). When arranged according to their mean age, trials
formed four clusters (very young and young children, and non-
elderly and elderly adults); and there was one single trial in adoles-
cents (9 to 17 years). We captured this pattern by forming four
mean age classes (1 to 2.5, 3 to 6, 30 to 55, and greater
than 65 years) and leaving the single trial unclassified.
Aqueous IIV: Most frequently, the aqueous comparators were
subunit and split vaccines, and in some cases also whole virus
and liposomal vaccines. Based on our previous study [4], these vac-
cine types were regarded similarly immunogenic and treated as
one entity. In six trials, two aqueous vaccines were included; these
trial arms were combined
Haemagglutinin and squalene amounts. Most vaccines (73%)
contained a total amount of 15 lg viral haemagglutinin (HA) per
strain, given either at one occasion (typically for adults) or at
two occasions with half the total amount (typically for children).
Also smaller (7.5 lg) and larger (30 lg) HA amounts were tested,
in three trial arms even 60 lg. In 90% of trial arms, squalene-IIV
and aqueous IIV contained the same HA amount, in the other
10% the HA amount in squalene-IIV was smaller than that in corre-
sponding aqueous IIV (dose sparing approach). The standard squa-
lene amount in adjuvanted IIV, 9.75 mg per vaccine dose, was used
in most trials (69%). For trials, which did not report the squalene
amount but mentioned the use of a commercially available brand
like FluadTM, the amount was imputed as being 9.75 mg per vaccine
dose. Some trials presented the squalene amount as volume (or
percentage of total vaccine volume), which was multiplied by the
density of squalene (0.585 g/cm3) to receive the mass amount
per dose. In some trials with experimental pandemic vaccines, also
smaller amounts than the standard were tested. In provisional
meta-regression models, positive associations between squalene
and HA amount on the one hand, and the endpoints (see below)
on the other hand, could be detected after adjustment for mean
age, but they were quantitatively negligible in this data collection.
When formulations were classified as either standardised (com-
mercial) or investigative (developmental, experimental), the distri-
butions of GMTR estimates in the two formulation classes were
similar. Thus, no adjustments for squalene or HA amounts were
applied. When a trial had more than one squalene arm, or more
than one HA arm, these trial arms were combined.
2.3. Endpoints representing adjuvant effect. Statistical methods.
Geometric mean titre ratio (GMTR). From a randomised,
paired comparison between squalene-IIV and aqueous IIV, the ratio
(quotient) between the post-GMT estimate of squalene-IIV and
that of aqueous IIV (GMTR) was calculated, and a 95% confidence
interval (CI) for the GMTR estimate was derived from the standard
deviations of the two post-GMT estimates, as described in [4]. A
GMTR value larger than 1 would favour squalene-IIV over aqueous
IIV, and vice versa. In the context of non-inferiority and superioritytesting, squalene-IIV was regarded non-inferior to aqueous IIV
when the lower limit of the CI of their GMTR exceeded 0.67-fold,
and superior when it exceeded 1.5-fold. Meta-analytical (pooled)
GMTR values and their CIs were calculated using the inverse
variance-weighted method according to Sutton et al. [7].
Protection rate difference (PRD). As described previously [8],
post-GMT values and their variances were transformed to
antibody-predicted protection rate (PRab) estimates using the clini-
cal protection curve by Coudeville et al. [9]. Per comparison, the pro-
tection rate difference (PRD) was formed from the PRab estimates of
squalene-IIVandaqueous IIV.APRDvalue larger than0would favour
squalene-IIV, and vice versa. Limits for a 95% confidence interval
around a PRD value were obtained, by means of bootstrapping, as
the 2.5th and 97.5th percentile of a set of 1,000,000 bootstrap esti-
mates as described [10]. For non-inferiority and superiority testing,
no acceptedmargins for PRDare available. Arbitrarily, the respective
margins were set at10% and 10%.
Other details on data extraction, statistical methods, in particu-
lar meta-regression, and software used, were described previously
[4,8]. Significance level in all procedures was 0.05.3. Results
3.1. Sources and properties of data collection
Our previous meta-analysis study had already identified 33 can-
didate articles. The renewed literature search identified titles and
abstracts of 184 articles. From 25 meta-analyses and reviews (Sup-
plementary Material 1), many of these published after 2009,
another 168 references were contributed. In total, 385 candidate
articles were considered and 336 excluded, for the reasons given
in the flowchart (Fig. 1).
Thus, 49 articles, each describing one eligible trial, were identi-
fied (Supplementary Material 2). In total, 155 groups of persons
had undergone any kind of intervention (treatment arms). Of them,
23 were excluded for reasons indicated in Fig. 1, and 132 treatment
arms with either squalene-adjuvanted or aqueous IIV were
extracted. When appropriate, treatment arms were combined with
respect to HA or squalene amounts, and others divided with
respect to mean age or health state. As vaccines contained one or
more virus antigens, a treatment arm could include one or more
sets of antibody data, resulting in 290 virus (sub-)type arms, thus
145 comparison pairs squalene-IIV versus aqueous IIV with homol-
ogous titration. Of these, 30 comparison pairs provided also anti-
body data with heterologous titration.
The entire collection of eligible trial arms comprised 22,470
persons of all ages, with 56.4% older people. More than half of
the participants (56.1%) were explicitly described as healthy, and
another large part (38.5%) included both healthy people and per-
sons with age-related chronic conditions (‘‘mixed” health state).
Few trials were performed in people with defined diseases, e.g.,
HIV infection. Not all articles reported the percentage of persons
with influenza vaccination preceding the trial, but in those that
did, the majority of persons (77.6%) had not received influenza vac-
cine previously.3.2. Homologous titrations – overview
For an overview and regardless of virus (sub-)type, the 290 sin-
gle post-GMT values were arranged according to mean age
(Fig. 2A). Young children up to five years, and adults from 30 years
onwards were well represented, but there was a data gap for ado-
lescents and younger adults. At any mean age on the x-axis, the
distance between best-fitting quadratic meta-regression lines for
squalene-IIV (orange) and aqueous IIV (blue) expresses the average
Fig. 1. Flow of literature retrieval. Numbers of articles and trial arms. Numbers and characteristics of study participants.
Fig. 2. Homologous post-vaccination antibody level according to (A) mean age, and (B) pre-vaccination antibody level. Symbols represent the post-vaccination GMT
estimates (290 trial arms). General tendency for all virus (sub-)types combined, was visualised by meta-regression lines (A: quadratic regression, B: linear regression),
separately for squalene-IIV and aqueous IIV.
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Fig. 3. Homologous adjuvant effect according to mean age. Symbols represent adjuvant effect estimates (145 comparisons squalene-IIV versus aqueous IIV) and their 95% CIs,
sorted and classified by mean age, for antibody level (A) and antibody-predicted protection level (B). Trial numbers correspond to the original articles in Supplementary
Material 2. When a trial number occurs more than one time, the respective trial provided data stratified for different age ranges. Red rectangle: trial number 02 [11] (see
Discussion).
1618 W.E.P. Beyer et al. / Vaccine 38 (2020) 1614–1622adjuvant effect. The distance was large at youngest age. With
increasing mean age (up to ~6 years), post-GMT values of aqueous
IIV tended to increase stronger than those of squalene-IIV suggest-
ing a decreasing adjuvant effect. At high age, post-GMT values of
the two vaccines converged.
When the same post-GMT values were arranged according to
pre-GMT values (Fig. 2B), the distance between the meta-
regression lines (best-fitting here: linear) was largest in sero-
negative persons (pre-GMT < 10), and shrank with increasing
pre-GMT.
This overview suggests that the average adjuvant effect is not a
constant, but is associated with measures of pre-seasonal
immunity: generally higher in younger and lower in older persons.
It appears that the fraction of primed and (frequently) exposed
persons in a trial limits the trial outcome related to the adjuvant
effect.3.3. Homologous titrations – adjuvant effect according to virus
(sub-)type and mean age
Fig. 3 presents the GMTR and PRD values of all 145 single com-
parisons between squalene-IIV and aqueous IIV, arranged accord-
ing to increasing mean age and distinct for virus (sub-)types.
Table 2 (left part) provides the meta-analysed means for the
respective mean age classes.
On the antibody level (GMTR values, Fig. 3A), virtually all GMTR
values in the youngest age class (2.5 years) were significantly ele-
vated. With increasing mean age, GMTR values decreased. Children
3 to 6 years still showed elevated values, but 95% confidence inter-
vals often included 1.0. In adults (30 to 55 years, and 65 years),
most GMTR values were slightly larger than 1.0 with 95% CIs
including 1.0. In older adults, only few trials (with tri-valent vacci-
nes) showed a significant adjuvant effect for all three vaccine com-
Table 2
Meta-analysed GMTR and PRD for age classes and virus (sub-)types. [Two pages]
Influenza (sub-)type Titration Homologous Heterologous
Mean age class (years) 1 to 2.5 3 to 6 13 30 to 55 65 1 to 2.5 3 to 6 30 to
55
65
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Confidence intervals were not calculated for classes < 3.
(*) Estimate dependent on year of trial. In a linear meta-regression model weighed by inverse variance, GMTR was 4.2-fold in 2009, and 1.7-fold in 2015.
(**) Non-inferior when lower limit of 95% CI exceeds 0.67-fold.
(***) Superior when lower limit of 95% CI exceeds 1.5-fold.
(#) Non-inferior when lower limit of 95% CI exceeds 10%.
(##) Superior when lower limit of 95% CI exceeds 10%.
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tioned in the Discussion). The pattern of decreasing adjuvant effect
estimates was similar for the four virus (sub-)types (Table 2).
When data for all (sub-)types were combined to grand averages
(lower part of Table 2), squalene-IIV induced 3.7-fold (95% CI: 2.5
to 5.5) larger GMT than aqueous IIV in the youngest age class,
and 1.4-fold (1.0 to 1.9) in older adults. Non-inferiority of
squalene-IIV versus aqueous IIV was demonstrated in most com-
parisons, regardless of age (100% in young children, 93% in older
adults), but superiority was predominantly found in children
(90% of comparisons in young children, 9% in older adults).
The pandemic A-H1N1 strain showed three particular fea-
tures. First, most pre-GMT values were smaller than the HI
detection threshold of 10 in 2009 and generally increased in tri-als performed in consecutive years, modestly for children < 2.5
years and adults (average pre-GMT in 2015: 10 to 22), but lar-
gely for the mean age class 3 to 6 years (average pre-GMT in
2015: 97). Second, the GMTR values in the younger age classes
were large, but while those of children < 2.5 years remained
large in the consecutive years, those in the 3 to 6 years class
remarkably dropped from 4.2-fold to 1.7-fold. Third, in the
two adult age classes, GMTR values were close to 1.0 already
in 2009, and remained low during the consecutive years. The
pandemic strain behaved like a seasonal one with respect to
the adjuvant effect.
On the level of antibody-predicted protection (PRD values,
Fig. 3B), most estimates for influenza A were smaller than 10%,
even in children; the meta-analysed grand PRD for all influenza
1620 W.E.P. Beyer et al. / Vaccine 38 (2020) 1614–1622A subtypes was 8.6% (95% CI: 5.9 to 11.5%) in the mean age class 1
to 2.5 years, and 7.8% (6.0 to 9.8%) in the mean age class 3 to
6 years. For influenza B in the same mean age classes, however,
meta-analysed PRD values were clearly larger than for influenza
A: 20.0% (16.1 to 23.9%) and 17.3% (14.2 to 20.5%), respectively.
A possible explanation for this distinction between influenza types
will be discussed. In the adult classes, individual and meta-
analysed PRD values were mostly close to 0% for both influenza
types, and no significant adjuvant effect was detected. The fraction
of comparisons showing superiority of adjuvanted over non-
adjuvanted IIV declined from 43% in the youngest mean age class
to 2% in older persons.3.4. Heterologous titrations
In twelve studies (Supportive Material [B]), also heterologous
titrations were performed in order to predict the performance of
the vaccine in case of a mismatch. After subdivision into treatment,
mean age, and virus (sub-)type trial arms, 60 trial arms and 30
comparisons were available. Results should be interpreted cau-
tiously, as often small subsets of available sera were titrated, which
decreased statistical power. Moreover, the trials differed in the
choice of titration viruses. Four classes of simulated antigenic mis-
match could be formed:
1. Retrospective titration (eleven comparisons): Vaccine and titra-
tion viruses belonged to the same influenza A subtype or influ-
enza B lineage, but the titration virus was ‘older’ than the
vaccine virus. E.g., in the study by Zedda et al. 2015 [12], sera
of persons vaccinated with B/Brisbane/60/2008 (Victoria) were
titrated against B/Malaysia/2506/2004 (Victoria), a strain iso-
lated four years earlier than the vaccine virus. The relevance
of these data to predict future mismatch may be limited.
2. Prospective titration - antigenic drift mismatch (thirteen com-
parisons). Here, the titration virus was ‘younger’ than the vac-
cine virus, still within the same influenza A subtype or
influenza B lineage, e.g., B/Yamagata/16/88 (vaccine strain)
and B/Panama/45/90 (titration strain) in the study by Minutello
et al. 1999 [13].
3. Prospective titration - influenza B lineage mismatch (five com-
parisons). E.g., B/Florida/4/2006 (Yamagata) and B/Bris-
bane/60/2008 (Victoria) in the study by Vesikari et al. 2011 [14].
4. Prospective titration - antigenic shift mismatch (one compar-
ison). This single study titrated sera raised against the last
pre-pandemic A-H1N1 vaccine strain A/Brisbane/59/2007 with
the pandemic strain A/California/7/2009 in older adults (Song
et al. 2013 [15]).
The numbers of comparisons per titration classwere too small to
analyse the data separately for each mismatch class, which would
have been desirable seen the biological differences between classes.
Surprisingly yet, when the GMTR and PRD values from all compar-
isons together were arranged according to increasing mean age
(Fig. 4), they appeared to mirror their homologous counterparts. As
confirmed by meta-analysis (Table 2 right part), the average adju-
vant effect was large in young children but small in older persons.4. Discussion
Clinical evidence for the effect of squalene as an adjuvant to
inactivated influenza vaccine was reviewed in a systematic collec-
tion of published immunogenicity trials. The extent of the adjuvant
effect was found to be associated with pre-seasonal immunity
(pre-vaccination HI antibody level and mean age): on average, it
was larger in young children, decreasing in older children andyoung adults, and barely detectable in older adults. The finding
applied for vaccines antigenically matched with circulating strains
(homologous titration) and also for antigenically mismatched vac-
cines (heterologous titration, performed in fewer trials). It applied
for seasonal A-H3N2, A-H1N1 and B strains, and the 2009 pan-
demic strain, but it is not necessarily predictive for future pan-
demic strains.
Pre-seasonal immunity against influenza viruses comprises all
innate and adaptive immune functions, which contribute to the
protection against upcoming influenza infection and disease (for
review see [16]). Adaptive immunity is strongly age-related as
exposure events accumulating in lifetime, modulate immune func-
tions [17]. The very first influenza A exposure and infection (prim-
ing) usually occurs early in lifetime: more than 90% of seven-years-
old children already carry anti-A antibodies, according to Bodewes
et al. 2011 [18] and Sauerbrei et al. 2014 [19]. In general, the first
influenza B infection occurs later in lifetime. At the age of seven
years, Bodewes et al. found ~70%, and Sauerbrei et al. ~35% anti-B
seropositivity. Interestingly, also our data show a virus type dis-
tinction at young age, related to the level of antibody-predicted
protection: The meta-analysed protection rate differences of the
two youngest age classes (six years) are larger for influenza B
than for influenza A (Fig. 3B, Table 2). It seems that the fraction
of naive children was larger for influenza B, and received a larger
benefit from adjuvant, than for influenza A. Unfortunately, trials
performed in older children and adolescents are not available to
confirm this trend. At adult age, when virtually every person has
experienced influenza A and B priming and accumulated exposure
events during lifetime, the virus type distinction can no longer be
demonstrated.
Not unexpectedly, the extent of the squalene adjuvant effect
appears to be ruled by the individual history of influenza exposure
events and the consecutive modulation of the immune system;
most benefit is provided to the unprimed. Immunogenicity trials
with vaccines containing influenza A-H5N1, an avian subtype not
circulating in the human population, have found a strong squalene
adjuvant effect in all ages. E.g., in the meta-analysis by Feldstein
et al. 2016 [20] including 22 A-H5N1 immunogenicity trials in
healthy persons aged 18 to 99 years, the meta-analysed GMT of
adjuvanted vaccines was found 3.5-fold larger than that of non-
adjuvanted vaccines. Similarly, we found a grand average of 3.7-
fold in the youngest mean age class (1 to 2.5 years, Table 2).
Support comes also from studies in naive and primed animals.
E.g., the experiments by Higgins et al. 1996 [21] in BALB/c mice
aged eight weeks, vaccinated with aqueous or squalene-
adjuvanted trivalent vaccines and assayed by a total Ig ELISA,
demonstrated a strong adjuvant effect for all three vaccine compo-
nents: 12-, 13- and 31-fold for A-H3N2, A-H1N1 and B, respec-
tively. However, when eight weeks old mice were first infected
by an A-H1N1 virus strain and vaccinated ten weeks thereafter,
no adjuvant effect was found (1.0-, 1.3- and 1.1-fold), remarkably
not only for A-H1N1, but also for A-H3N2 and B, suggesting that
the priming event be a hetero(sub-)typic phenomenon in mice.
When the same experiments were done in 18 months old mice, a
moderate adjuvant effect did occur: 3.9-, 2.4- and 7.5-fold, respec-
tively. The authors predicted that squalene may improve antibody
induction of IIV in older humans to the same extent as in old mice;
yet, they also note that the old mouse model may not well repre-
sent the human older population: the mice were infected only
once, while older humans have experienced many influenza infec-
tions during lifetime.
A negative association between effect and pre-seasonal immu-
nity had been found not only for squalene-adjuvanted IIV, but also
for live attenuated influenza vaccine (versus IIV) [22] and quadriva-
lent IIV in case of influenza B lineage mismatch (versus trivalent
IIV) [8]. It seems that some important vaccine innovations of the
Fig. 4. Heterologous adjuvant effect according to mean age. Symbols represent adjuvant effect estimates (30 comparisons squalene-IIV versus aqueous IIV) and their 95% CIs,
sorted and classified by mean age, for antibody level (A) and antibody-predicted protection level (B). Trial numbers correspond to the original publications in Supplementary
Material 2. Mismatch: R, retrospective titration; D, drift mismatch; B, influenza B lineage mismatch; S, shift mismatch. Trial 23 included 14 clade- and drift-variants of the
vaccine virus A/California/7/2004 (H3N2); here, the variant A/Genoa/47/2005 is presented.
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cial for unprimed children, but of more limited value in older
adults.
A strong feature of our investigation may be the sheer number
of observations: 145 comparison pairs in 22,470 persons of all
ages. Single trials are modulated by various geographic, seasonal,
societal and individual factors unrelated to vaccination; the
inter-trial variation of influenza studies is notorious. Only a suffi-
ciently large number of trials identified by systematic search,
may reveal a representative pattern. To generalise results from sin-
gle trials to entire populations, may sometimes be inappropriate. E.
g., a review article on squalene as a vaccine adjuvant [1] presented
just one comparative immunogenicity trial in older persons (of
more than ten possible trials) and then seemed to claim superiority
of squalene-adjuvanted IIV in older populations in general. The
cited trial was one of the few, which did show a significant adju-
vant benefit for all three vaccine components [11]. In most other
elderly trials, at least one vaccine component induced just similar
antibody levels in adjuvanted and aqueous trial arms. Inspection
(Fig. 3) and meta-analysis (Table 2) of the entire data collectiondo not support the claim that squalene IIV is superior to aqueous
IIV in older persons.
As a limitation, our findings are entirely based on trials measur-
ing antibody, which do not necessarily directly assess real vaccine
effectiveness in the field. But given the association between HI
antibody and the chance of protection as established by Coudeville
et al. [9], we explored protection rates predicted from antibody dis-
tributions and found a pattern similar to the antibody level. It
would be desirable if these predictions could be confirmed by
observations in the field. The classical study design to compare
two vaccines is the randomised comparative trial (RCT) with speci-
fic (laboratory-confirmed) endpoints. However, a large number of
volunteers would be required to detect a truly existing adjuvant
benefit. The RCT by McElhany et al. [23] comparing another adju-
vanted IIV (AS03B formulation containing 5.93 mg a-tocopherol
and 5.93 mg squalene per vaccine dose) with aqueous IIV, included
more than 40,000 vaccinees. An alternative study design requiring
less participants, may be the test-negative case-control trial (tn-
CCT) in care-seeking persons [24]. A current standardized protocol
on brand-specific tn-CCT (DRIVE report 2018 [25]) recommends a
1622 W.E.P. Beyer et al. / Vaccine 38 (2020) 1614–1622number of at least 1000 (cases and controls) when the combined
true vaccine effectiveness is at least 50%, the attack rate during epi-
demic at least 5%, and the vaccine coverage at least 20%. Other
observational study designs, like cohort and case-control, carry
large risks of bias and confounding, and cannot be recommended
to assess relative vaccine effectiveness.
To our knowledge, no RCT to compare the field effectiveness of
squalene-IIV with that of aqueous IIV has ever been performed.
Domnich et al. [26] identified five comparative field trials in older
persons (two cohort trials, two case-control trials, and one tn-CCT),
of which three used non-specific (clinically defined) endpoints and
two laboratory-confirmed endpoints. Mostly due to low virus cir-
culation, numbers of endpoint cases were small. E.g., the tn-CCT
by Van Buynder et al. [27] included 282 participants, of whom 84
were cases - numbers far below the DRIVE recommendations men-
tioned above. Three of the field trials detected an adjuvant benefit
of borderline significance, the other two did not find a significant
distinction between squalene-IIV and aqueous IIV. Thus, the avail-
able evidence from field trials can be regarded as limited. If any-
thing, it would support our finding in antibody trials, namely
that the additional benefit of squalene in older persons is small.
Surprisingly, the review by Domnich et al. concludes that ‘‘the
available evidence suggests that MF59-TIV is . . . superior to conven-
tional non-adjuvanted vaccines”. But we do agree with their call
for ‘‘well-designed and sufficiently powered” comparative field trials
in older persons, with the restraint that trials of even the highest
quality can barely detect an adjuvant effect.
In summary, our findings from comparative immunogenicity
trials has found evidence for a negative association between adju-
vancy and pre-seasonal immunity. Squalene-adjuvanted IIV may
not significantly overcome the inferior vaccine effectiveness of
aqueous IIV often found in older adults, but is more effective than
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